Table 4

Factors for belonging to treatment-resistance group identified by univariable and multivariable logistic regression analyses by treatment group

TOFA (n=156)BARI (n=138)
Univariable analysisMultivariable analysisUnivariable analysisMultivariable analysis
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Age1.03 (0.99–1.06)0.051.01 (0.98–1.05)0.491.02 (0.98–1.06)0.38
Sex (female)0.87 (0.33–2.24)0.770.92 (0.28–3.04)0.89
RA duration1.00 (0.99–1.01)0.501.00 (0.99–1.01)0.111.00 (0.99–1.00)0.851.00 (0.99–1.01)0.24
MTX dose0.94 (0.89–0.99)0.040.97 (0.90–1.04)0.401.00 (0.92–1.07)0.84
Number of previous bDMARDs used1.60 (1.20–2.07)<0.0011.77 (1.26–2.48)<0.0011.31 (0.97–1.78)0.081.41 (0.95–2.10)0.09
HAQ-DI2.26 (1.36–3.77)0.0011.86 (1.02–3.39)0.042.34 (1.19–4.59)0.01
CRP1.13 (1.01–1.27)0.041.10 (0.97–1.26)0.151.11 (0.97–1.27)0.13
MMP-31.00 (0.99–1.00)0.141.00 (0.99–1.00)0.26
Rheumatoid factor titre1.00 (0.99–1.00)0.631.00 (0.99–1.00)0.31
Anti-CCP antibody titre1.00 (0.99–1.00)0.961.00 (0.99–1.01)0.231.01 (1.00–1.02)0.031.00 (0.99–1.01)0.09
  • BARI, baricitinib; bDMARDs, biological disease-modifying antirheumatic drugs; CCP, cyclic citrullinated peptide; CRP, C reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP-3, matrix metalloproteinase 3; MTX, methotrexate; RA, rheumatoid arthritis; TOFA, tofacitinib.